Skip to main content
Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
22.32
+0.29 (1.32%)
At close: Mar 9, 2026, 4:00 PM EDT
22.76
+0.44 (1.97%)
After-hours: Mar 9, 2026, 4:06 PM EDT

Innoviva Revenue

In the year 2025, Innoviva had annual revenue of $411.33M with 14.67% growth. Innoviva had revenue of $114.61M in the quarter ending December 31, 2025, with 24.84% growth.

Revenue (ttm)
$411.33M
Revenue Growth
+14.67%
P/S Ratio
4.02
Revenue / Employee
$2,586,969
Employees
159
Market Cap
1.65B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025411.33M52.62M14.67%
Dec 31, 2024358.71M48.25M15.54%
Dec 31, 2023310.46M-20.88M-6.30%
Dec 31, 2022331.34M-60.53M-15.45%
Dec 31, 2021391.87M55.07M16.35%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Novavax 1.12B
Harmony Biosciences Holdings 868.45M
Immunocore Holdings 400.02M
AnaptysBio 234.60M
Intellia Therapeutics 67.67M
Agios Pharmaceuticals 54.03M
Nanobiotix 11.93M
Oculis Holding AG 1.51M
Revenue Rankings

INVA News

More News